ITF Therapeutics shares publication of long-term data showing givinostat can delay loss of functional abilities in Duchenne

Results published in the Annals of Clinical and Translational Neurology show that long-term treatment with givinostat, a histone deacetylase (HDAC) inhibitor, in combination with corticosteroids, delayed disease progression in ambulant individuals with DMD.  Compared with natural history controls, individuals receiving givinostat showed positive impacts on time to rise from the floor, four stair climb, and ambulation.  These new findings show that givinostat (marketed by ITF as DUVYZAT) continues to show benefits for individuals, and that over the long-term the treatment remains safe and tolerable.  

Press release: